- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01268839
A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
September 2, 2013 updated by: Tibotec, Inc
A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Subjects
The purpose of this study is to investigate the pharmacokinetics of TMC278 (rilpivirine) 25 mg once daily following a preceding 2-week treatment period with efavirenz 600 mg once daily in healthy volunteers
Study Overview
Detailed Description
This is a Phase I, open-label (all people involved know the identity of the intervention), single center trial in healthy HIV negative volunteers to investigate the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body, the rate at which a drug action begins, the duration of the effect, the chemical changes of the substance in the body, and the effects and routes of excretion of the metabolites) of the drug of rilpivirine (TMC278) 25 mg once daily (q.d.).
An approximate total of 20 volunteers will be enrolled in this trial.
All volunteers will receive 3 different treatments; o Treatment A: TMC278 25 mg q.d.
administered for 14 days.;
o Treatment B: efavirenz (EFV) 600 mg q.d.
administered for 14 days.;
o Treatment C: TMC278 25 mg q.d.
administered for 28 days (4 weeks).;
All volunteers will start with Treatment A followed by Treatment B. Treatments A and B will be separated by a washout period of at least 14 days but no more than 21 days.
At the end of Treatment B, volunteers will continue with Treatment C.
There will be no washout period between Treatments B and C.; Full pharmacokinetic profiles of TMC278 will be determined up to 24 hours postdose on Days 1 and 14 of Treatment A (references), Day 1 (immediately after cessation of EFV intake) of Treatment C (test), and on Days 14, 21, and 28 (2, 3, and 4 weeks after cessation of EFV intake, respectively) of Treatment C. Trough (C0h) samples for determination of TMC278 plasma; concentrations will be collected regularly in between.
Blood samples for determination of EFV plasma concentrations will be collected at regular time points during Treatment B and during Treatment C after cessation of EFV intake.;
Serum samples for potential future testing of ex vivo antiviral activity will be collected and stored.;
A pharmacogenomic blood sample for potential future CYP2B6 genotyping will be collected and stored from subjects who consent separately to the pharmacogenomic component of the trial.;
Safety and tolerability will be evaluated throughout the trial.
Rilpivirine (TMC278) 25mg once daily for 14 days, No Treatment 14-21 days, Efavirenz 600mg once daily for 14 days, TMC278 25mg once daily for 28 days
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non-vasectomized heterosexually active male volunteers with female partner of childbearing potential must be using a highly effective method of birth control (i.e., male condom with either female intrauterine device, diaphragm, cervical cap or hormonal based contraceptives) and must agree to use these birth control methods during the trial and until 30 days after the end of the trial
- Able to comply with all protocol requirements
- Normal resting ECG at screening including
- Volunteers must have signed an Informed Consent Form (ICF) voluntarily before the first trial-related activity indicating that they understand the purpose of and procedures required for the trial and are willing to participate in the trial
- To participate in the optional pharmacogenomic component of this trial, volunteers must have signed the ICF for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the trial. Refusal to give consent for this component does not exclude a volunteers from participation in the clinical trial
- Healthy on the basis of a medical evaluation that confirms the absence of any clinically relevant abnormality and includes a physical examination (including skin examination), medical history, vital signs, the results of blood biochemistry and hematology tests and a urinalysis carried out at screening.
Exclusion Criteria:
- A positive HIV-1 or -2 test at trial screening
- Females of childbearing potential
- Hepatitis A infection (confirmed by hepatitis A antibody IgM), hepatitis B infection (confirmed by hepatitis B surface antigen), or hepatitis C infection (confirmed by hepatitis C virus antibody) diagnosed at trial screening
- Currently active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or findings during screening of medical history, laboratory or physical examination that in the investigator's opinion would compromise subject safety or the outcome of the trial
- Current or recent (within 3 months prior to the first administration of trial medication) gastrointestinal disease
- Any history of significant skin disease such as but not limited to rash or eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria
- A positive alcohol test or urine drug test at study screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
|
25mg tablet once daily for 28 days
25mg tablet once daily for 14 days
600mg tablet once daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of TMC278 25 mg once daily (q.d.) following a preceding 2-week treatment period with EFV 600 mg q.d., in healthy volunteers
Time Frame: 70-77 days
|
70-77 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the EFV inducing effect on TMC278 metabolism after EFV intake cessation, through comparison of TMC278 plasma concentrations with and without preceding EFV intake
Time Frame: 70-77 days
|
70-77 days
|
To evaluate EFV plasma concentrations over time after cessation of EFV intake
Time Frame: 70-77 days
|
70-77 days
|
To assess the safety (including vital signs and electrocardiogram [ECG] measurements, laboratory assessments, and incidence of overall AEs and tolerability) of TMC278 at a dose of 25 mg q.d administered alone and after switching from EFV over a period of
Time Frame: 70-77 days
|
70-77 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Tibotec, Inc. Clinical Trial, Tibotec, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
May 1, 2010
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
December 30, 2010
First Submitted That Met QC Criteria
December 30, 2010
First Posted (Estimate)
December 31, 2010
Study Record Updates
Last Update Posted (Estimate)
September 4, 2013
Last Update Submitted That Met QC Criteria
September 2, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Efavirenz
- Rilpivirine
Other Study ID Numbers
- CR016984
- TMC278HIV1001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on TMC278
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Janssen Research & Development, LLCCompleted
-
Tibotec Pharmaceuticals, IrelandCompletedHepatitis C | HIVBelgium
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)Unknown
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedLymphoma | Leukemia | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
Tibotec Pharmaceuticals, IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, China, Germany, South Africa, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Thailand, Mexico, Uganda
-
Janssen R&D IrelandCompleted
-
Janssen Research & Development, LLCCompletedHIVItaly, Thailand, Spain, Uganda, Portugal, South Africa